Mouse Anti-CD38 Recombinant Antibody (clone OKT10) (CAT#: HPAB-0379-FY)

Figure 1 Pre-incubation of Nalm-6 cells with blocking (SUN-4B7) and nonblocking (OKT10) anti-CD38 mAbs and anti-CXCR4 mAbs differently interferes with homing to spleen and BM.

Cumulative data from at least six animals per condition (a). Total number of human cells (CD19+) out of 105 events is shown. (b) Homing of freshly purified PBMCs from CLL patients was studied using the same model. Data were analyzed by morphological gating on lymphocytes (R1) and subsequently on the CD45+ subset (R2). The CD19/CD5 fluorescence levels were then determined for cells contained in R3 (R1 × R2). (c) Pre-incubation with blocking anti-CD38 mAb (SUN-4B7) negatively interferes with homing of CLL lymphocytes to spleen and BM. Anti-CXCR4 mAb was used as the positive control, whereas an isotype-matched (IgG1) anti-CD38 mAb (OKT10) was used as a binding but nonblocking control mAb. Results are presented as mean±s.e.m. of eight independent experiments, with each condition analyzed in duplicate.

Vaisitti, T., Aydin, S., Rossi, D., Cottino, F., Bergui, L., D'arena, G., ... & Gaidano, G. (2010). CD38 increases CXCL12-mediated signals and homing of chronic lymphocytic leukemia cells. Leukemia, 24(5), 958.

Figure 2 Binding of anti-CD38 antibody constructs to CD38 on malignant plasma cells.

Competitive binding assays demonstrate blocking of Alexa-647–conjugated OKT10 mAb binding to CD38-expressing L363 multiple myeloma cells with escalating concentrations of unlabeled OKT10-FP (A) or OKT10-CC (B). No blocking is observed with escalating concentrations of nonbinding control Ab constructs.

Green, D. J., Orgun, N. N., Jones, J. C., Hylarides, M. D., Pagel, J. M., Hamlin, D. K., ... & Frayo, S. L. (2014). A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer research, 74(4), 1179-1189.

Figure 3 A detailed organ dosimetry analysis was performed to calculate 90Y absorbed dose estimates after OKT10-CC pretargeting.

90Y absorbed dose estimates (Gy/mCi) from an 111In–DOTA–biotin tracer. Radiation absorbed doses to tumor, whole body, and normal tissues are estimated by integrating the areas under time–activity curves constructed by plotting the concentration of 111In–DOTA–biotin (after OKT10-CC pretargeting) measured in tissues by γ counting at 2, 24, 48, and 96 hours (33).

Green, D. J., Orgun, N. N., Jones, J. C., Hylarides, M. D., Pagel, J. M., Hamlin, D. K., ... & Frayo, S. L. (2014). A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies. Cancer research, 74(4), 1179-1189.